{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:41:44Z","timestamp":1782337304433,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105045","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:03:38Z","timestamp":1763762618000},"page":"105045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Venetoclax and ibrutinib: Two partners for the front-line treatment of chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"217","author":[{"given":"Andrea","family":"Visentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angotzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2425-9474","authenticated-orcid":false,"given":"Francesca Romana","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2025.105045_bib1","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105045_bib2","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax, phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105045_bib3","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1158\/1078-0432.CCR-22-0504","article-title":"Effective tumor debulking with ibrutinib before initiation of venetoclax, results from the CAPTIVATE minimal residual disease and fixed-duration cohorts","volume":"28","author":"Barr","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105045_bib4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105045_bib5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-na\u00efve chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids","year":"2025","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105045_bib6","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1158\/1078-0432.CCR-18-1286","article-title":"Ibrutinib therapy releases leukemic surface igm from antigen drive in chronic lymphocytic leukemia patients","volume":"25","author":"Drennan","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"S1","key":"10.1016\/j.critrevonc.2025.105045_bib7","article-title":"Hybrid congress","volume":"8","author":"EHA","year":"2024","journal-title":"HemaSphere"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105045_bib8","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL association, and cancer trials ireland. first-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105045_bib9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.105045_bib10","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105045_bib11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13), 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105045_bib12","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.105045_bib13","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.105045_bib14","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"1010 Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105045_bib15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105045_bib16","article-title":"Combined pirtobrutinib, venetoclax, and obinutuzumab as first-line treatment of patients with chronic lymphocytic leukemia (CLL)","volume":"144","author":"Jain","year":"2024","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105045_bib17","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105045_bib18","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia, a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105045_bib19","first-page":"635","article-title":"Combined ibrutinib and venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL), 5-year follow-up data","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105045_bib20","doi-asserted-by":"crossref","first-page":"2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105045_bib21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41375-023-01898-w","article-title":"Eldering. Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation","volume":"37","author":"Kielbassa","year":"2023","journal-title":"Leukemia"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105045_bib22","article-title":"Improved Efficacy with Response- and MRD-guided ibrutinib-obinutuzumab (IO) intensification after ibrutinib-venetoclax (IV) in first line chronic lymphocytic leukemia (CLL) patients, primary analysis of the HOVON 158\/Next STEP phase 2 trial","volume":"144","author":"Levin","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105045_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104408","article-title":"Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors","volume":"201","author":"Mauro","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105045_bib24","article-title":"Minimal residual disease-guided combination of ibrutinib and venetoclax compared to FCR in untreated patients with CLL of intermediate risk, final results of the eradic trial from the filo group","volume":"144","author":"Michallet","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105045_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.27544","article-title":"Prevalence of BTK and PLCG2 mutations in CLL patients with disease progression on btk inhibitor therapy, a meta-analysis","volume":"100","author":"Molica","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105045_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105045_bib27","article-title":"IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax, Report of the UK NCRI FLAIR Study","volume":"144","author":"Munir","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105045_bib28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib\u2013venetoclax versus chlorambucil\u2013obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW), 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105045_bib29","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2024-203269","article-title":"First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL), Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis","volume":"144","author":"Niemann","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105045_bib30","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3324\/haematol.2018.209981","article-title":"p66Shc deficiency in the E\u03bc-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape","volume":"104","author":"Patrussi","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105045_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3324\/haematol.2022.282466","article-title":"Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia","volume":"109","author":"Rey-Barroso","year":"2023","journal-title":"Haematol"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105045_bib32","article-title":"Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Na\u00efve Chronic Lymphocytic Leukemia, 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (\u0394MRD400)","volume":"144","author":"Soumerai","year":"2024","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105045_bib33","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL, primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105045_bib34","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1038\/s41375-025-02778-1","article-title":"Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib","volume":"39","author":"Tedeschi","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.105045_bib35","unstructured":"The Surveillance E, and End Results (SEER) Program of the National Cancer Institute, Cancer Stat Facts, Leukemia\u2014Chronic Lymphocytic Leukemia (CLL) (2024)."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105045_bib36","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3390\/cancers16071290","article-title":"Innovative combinations, cellular Thera2024pies and bispecific antibodies for chronic lymphocytic leukemia, a narrative review","volume":"16","author":"Visentin","year":"2024","journal-title":"Cancers"},{"issue":"34","key":"10.1016\/j.critrevonc.2025.105045_bib37","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia, primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"JCO"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105045_bib38","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105045_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:49:52Z","timestamp":1768333792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"alternative-id":["S1040842825004330"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105045","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax and ibrutinib: Two partners for the front-line treatment of chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105045"}}